Global Chronic Kidney Disease

Chronic Kidney Disease Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug class (ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents (ESAs), Diuretics, Others) Players and Region - Global Market Outlook to 2030

Chronic Kidney Disease Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Chronic Kidney Disease
Chronic kidney disease is a kind of kidney disease in which there is a steady loss of kidney function over a period of months or years. Early on there are usually no symptoms. Later, leg swelling, vomiting, feeling tired, loss of appetite, or confusion may develop. Complications may include high blood pressure, heart disease, bone disease, or anemia. There are some drugs & medications are available to control the symptoms & associated problems including ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others. Based on the distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR3.8%


Chronic Kidney Disease is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Chronic Kidney Disease market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Amgen, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer, Inc. (United States), AstraZeneca Plc (United Kingdom), F. Hoffman La Roche Ltd. (Switzerland), Sanofi S.A. (France), Kissei Pharmaceutical Co. Ltd. (Japan), AbbVie, Inc. (United States), GlaxoSmithKline Plc (United Kingdom) and Keryx Biopharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Allergan plc. (Ireland), FibroGen (United States) and Johnson & Johnson (United States).

Segmentation Overview
AMA Research has segmented the market of Global Chronic Kidney Disease market by and Region.



On the basis of geography, the market of Chronic Kidney Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Chronic Kidney Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug class, the sub-segment i.e. ACE Inhibitors will boost the Chronic Kidney Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technology Advancement in Field Of Science

Market Growth Drivers:
Increasing Prevalence of Chronic Kidney Disease, Increasing geriatric population Among the Globe, High Presence of Generic Drug Manufacturers in the Market and Initiatives Taken By Government Organizations and Manufacturers to Increase Awareness

Restraints:
Delay in the Diagnosis of Chronic Kidney Disease

Opportunities:
Attractive Investment Proposition, Rapid Technological Advancements and Emerging Demand from Economies

Market Leaders and their expansionary development strategies
In January 2023, AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
In Dec 2018, AstraZeneca, a leading pharma company has announced the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease that are either dialysis-dependent or non-dialysis-dependent, respectively.


Key Target Audience
Chronic Kidney Disease Manufacturers, Chronic Kidney Disease Traders/Distributors, Chronic Kidney Disease Importer/Exporter, Regulatory Bodies, Government Bodies and Industry Associations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug class
  • ACE Inhibitors
  • Angiotensin-II receptor blockers
  • Calcium channel blockers
  • Beta blockers
  • Erythropoiesis-stimulating agents (ESAs)
  • Diuretics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Kidney Disease
      • 3.2.2. Increasing geriatric population Among the Globe
      • 3.2.3. High Presence of Generic Drug Manufacturers in the Market
      • 3.2.4. Initiatives Taken By Government Organizations and Manufacturers to Increase Awareness
    • 3.3. Market Trends
      • 3.3.1. Technology Advancement in Field Of Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chronic Kidney Disease, by Distribution Channel, Drug class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Chronic Kidney Disease (Value)
      • 5.2.1. Global Chronic Kidney Disease by: Distribution Channel (Value)
        • 5.2.1.1. Hospital Pharmacies
        • 5.2.1.2. Retail Pharmacies
        • 5.2.1.3. Online Pharmacies
      • 5.2.2. Global Chronic Kidney Disease by: Drug class (Value)
        • 5.2.2.1. ACE Inhibitors
        • 5.2.2.2. Angiotensin-II receptor blockers
        • 5.2.2.3. Calcium channel blockers
        • 5.2.2.4. Beta blockers
        • 5.2.2.5. Erythropoiesis-stimulating agents (ESAs)
        • 5.2.2.6. Diuretics
        • 5.2.2.7. Others
      • 5.2.3. Global Chronic Kidney Disease Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Chronic Kidney Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca Plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffman La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Kissei Pharmaceutical Co. Ltd. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Keryx Biopharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chronic Kidney Disease Sale, by Distribution Channel, Drug class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Chronic Kidney Disease (Value)
      • 7.2.1. Global Chronic Kidney Disease by: Distribution Channel (Value)
        • 7.2.1.1. Hospital Pharmacies
        • 7.2.1.2. Retail Pharmacies
        • 7.2.1.3. Online Pharmacies
      • 7.2.2. Global Chronic Kidney Disease by: Drug class (Value)
        • 7.2.2.1. ACE Inhibitors
        • 7.2.2.2. Angiotensin-II receptor blockers
        • 7.2.2.3. Calcium channel blockers
        • 7.2.2.4. Beta blockers
        • 7.2.2.5. Erythropoiesis-stimulating agents (ESAs)
        • 7.2.2.6. Diuretics
        • 7.2.2.7. Others
      • 7.2.3. Global Chronic Kidney Disease Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chronic Kidney Disease: by Distribution Channel(USD Million)
  • Table 2. Chronic Kidney Disease Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 3. Chronic Kidney Disease Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 4. Chronic Kidney Disease Online Pharmacies , by Region USD Million (2018-2023)
  • Table 5. Chronic Kidney Disease: by Drug class(USD Million)
  • Table 6. Chronic Kidney Disease ACE Inhibitors , by Region USD Million (2018-2023)
  • Table 7. Chronic Kidney Disease Angiotensin-II receptor blockers , by Region USD Million (2018-2023)
  • Table 8. Chronic Kidney Disease Calcium channel blockers , by Region USD Million (2018-2023)
  • Table 9. Chronic Kidney Disease Beta blockers , by Region USD Million (2018-2023)
  • Table 10. Chronic Kidney Disease Erythropoiesis-stimulating agents (ESAs) , by Region USD Million (2018-2023)
  • Table 11. Chronic Kidney Disease Diuretics , by Region USD Million (2018-2023)
  • Table 12. Chronic Kidney Disease Others , by Region USD Million (2018-2023)
  • Table 13. South America Chronic Kidney Disease, by Country USD Million (2018-2023)
  • Table 14. South America Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 15. South America Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 16. Brazil Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 17. Brazil Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 18. Argentina Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 19. Argentina Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 20. Rest of South America Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 21. Rest of South America Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 22. Asia Pacific Chronic Kidney Disease, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 24. Asia Pacific Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 25. China Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 26. China Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 27. Japan Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 28. Japan Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 29. India Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 30. India Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 31. South Korea Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 32. South Korea Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 33. Taiwan Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 34. Taiwan Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 35. Australia Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 36. Australia Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 39. Europe Chronic Kidney Disease, by Country USD Million (2018-2023)
  • Table 40. Europe Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 41. Europe Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 42. Germany Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 43. Germany Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 44. France Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 45. France Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 46. Italy Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 47. Italy Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 48. United Kingdom Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 49. United Kingdom Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 50. Netherlands Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 51. Netherlands Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 52. Rest of Europe Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 53. Rest of Europe Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 54. MEA Chronic Kidney Disease, by Country USD Million (2018-2023)
  • Table 55. MEA Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 56. MEA Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 57. Middle East Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 58. Middle East Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 59. Africa Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 60. Africa Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 61. North America Chronic Kidney Disease, by Country USD Million (2018-2023)
  • Table 62. North America Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 63. North America Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 64. United States Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 65. United States Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 66. Canada Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 67. Canada Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 68. Mexico Chronic Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 69. Mexico Chronic Kidney Disease, by Drug class USD Million (2018-2023)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Chronic Kidney Disease: by Distribution Channel(USD Million)
  • Table 81. Chronic Kidney Disease Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 82. Chronic Kidney Disease Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 83. Chronic Kidney Disease Online Pharmacies , by Region USD Million (2025-2030)
  • Table 84. Chronic Kidney Disease: by Drug class(USD Million)
  • Table 85. Chronic Kidney Disease ACE Inhibitors , by Region USD Million (2025-2030)
  • Table 86. Chronic Kidney Disease Angiotensin-II receptor blockers , by Region USD Million (2025-2030)
  • Table 87. Chronic Kidney Disease Calcium channel blockers , by Region USD Million (2025-2030)
  • Table 88. Chronic Kidney Disease Beta blockers , by Region USD Million (2025-2030)
  • Table 89. Chronic Kidney Disease Erythropoiesis-stimulating agents (ESAs) , by Region USD Million (2025-2030)
  • Table 90. Chronic Kidney Disease Diuretics , by Region USD Million (2025-2030)
  • Table 91. Chronic Kidney Disease Others , by Region USD Million (2025-2030)
  • Table 92. South America Chronic Kidney Disease, by Country USD Million (2025-2030)
  • Table 93. South America Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 94. South America Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 95. Brazil Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 96. Brazil Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 97. Argentina Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 98. Argentina Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 99. Rest of South America Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 100. Rest of South America Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 101. Asia Pacific Chronic Kidney Disease, by Country USD Million (2025-2030)
  • Table 102. Asia Pacific Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 103. Asia Pacific Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 104. China Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 105. China Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 106. Japan Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 107. Japan Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 108. India Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 109. India Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 110. South Korea Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 111. South Korea Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 112. Taiwan Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 113. Taiwan Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 114. Australia Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 115. Australia Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 116. Rest of Asia-Pacific Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 117. Rest of Asia-Pacific Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 118. Europe Chronic Kidney Disease, by Country USD Million (2025-2030)
  • Table 119. Europe Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 120. Europe Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 121. Germany Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 122. Germany Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 123. France Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 124. France Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 125. Italy Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 126. Italy Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 127. United Kingdom Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 128. United Kingdom Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 129. Netherlands Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 130. Netherlands Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 131. Rest of Europe Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 132. Rest of Europe Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 133. MEA Chronic Kidney Disease, by Country USD Million (2025-2030)
  • Table 134. MEA Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 135. MEA Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 136. Middle East Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 137. Middle East Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 138. Africa Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 139. Africa Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 140. North America Chronic Kidney Disease, by Country USD Million (2025-2030)
  • Table 141. North America Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 142. North America Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 143. United States Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 144. United States Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 145. Canada Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 146. Canada Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 147. Mexico Chronic Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 148. Mexico Chronic Kidney Disease, by Drug class USD Million (2025-2030)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chronic Kidney Disease: by Distribution Channel USD Million (2018-2023)
  • Figure 5. Global Chronic Kidney Disease: by Drug class USD Million (2018-2023)
  • Figure 6. South America Chronic Kidney Disease Share (%), by Country
  • Figure 7. Asia Pacific Chronic Kidney Disease Share (%), by Country
  • Figure 8. Europe Chronic Kidney Disease Share (%), by Country
  • Figure 9. MEA Chronic Kidney Disease Share (%), by Country
  • Figure 10. North America Chronic Kidney Disease Share (%), by Country
  • Figure 11. Global Chronic Kidney Disease share by Players 2023 (%)
  • Figure 12. Global Chronic Kidney Disease share by Players (Top 3) 2023(%)
  • Figure 13. Global Chronic Kidney Disease share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Amgen, Inc. (United States) Revenue: by Geography 2023
  • Figure 17. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 19. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 23. F. Hoffman La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffman La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 27. Kissei Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Kissei Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2023
  • Figure 29. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. AbbVie, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Keryx Biopharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Keryx Biopharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Global Chronic Kidney Disease: by Distribution Channel USD Million (2025-2030)
  • Figure 36. Global Chronic Kidney Disease: by Drug class USD Million (2025-2030)
  • Figure 37. South America Chronic Kidney Disease Share (%), by Country
  • Figure 38. Asia Pacific Chronic Kidney Disease Share (%), by Country
  • Figure 39. Europe Chronic Kidney Disease Share (%), by Country
  • Figure 40. MEA Chronic Kidney Disease Share (%), by Country
  • Figure 41. North America Chronic Kidney Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen, Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Pfizer, Inc. (United States)
  • AstraZeneca Plc (United Kingdom)
  • F. Hoffman La Roche Ltd. (Switzerland)
  • Sanofi S.A. (France)
  • Kissei Pharmaceutical Co. Ltd. (Japan)
  • AbbVie, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Keryx Biopharmaceuticals, Inc. (United States)
Additional players considered in the study are as follows:
Allergan plc. (Ireland) , FibroGen (United States) , Johnson & Johnson (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 217 Pages 63 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chronic Kidney Disease Quantitative research analysis
Global Chronic Kidney Disease Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Amgen, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer, Inc. (United States), AstraZeneca Plc (United Kingdom), F. Hoffman La Roche Ltd. (Switzerland), Sanofi S.A. (France), Kissei Pharmaceutical Co. Ltd. (Japan), AbbVie, Inc. (United States), GlaxoSmithKline Plc (United Kingdom) and Keryx Biopharmaceuticals, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technology Advancement in Field Of Science" is seen as one of major influencing trends for Chronic Kidney Disease Market during projected period 2023-2030.
The Chronic Kidney Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Chronic Kidney Disease Report?

Have a Query? Click Here

Other Related Reports

Androgen Deprivation Therapy Comprehensive Study by Type (Luteinizing Hormone-Releasing Hormone (LHRH) agonists, LHRH antagonists, Antiandrogens, Others), End-User (Hospitals, Clinics, Others), Admin...
$ 3450
Canine Arthritis Treatment Comprehensive Study by Type (Non-Steroidal Anti-Inflammatory Drugs, Opioids, Stem Cell Therapy), Application (Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stor...
$ 3650
Infectious Disease Testing Comprehensive Study by Type (Assays, Kits, & Reagents, Instruments, Services and Software), Disease Type (Hepatitis, HIV, CT/NG, HAIs, HPV, TB, Influenza, Others), Technolo...
$ 3750
Insulin Lispro Comprehensive Study by Type (Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution...
$ 3450
Infertility Treatment Comprehensive Study by Application (Fertility Centers, Hospitals and Surgical Clinics, Research Institutes, Cryobanks), Equipment (Microscopes, Imaging Systems, Incubators, Sper...
$ 3750
Pediatric Interventional Cardiology Comprehensive Study by Type (Congenital Heart Defect Closure Devices (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), and Patent Foramen Ovale (PFO) C...
$ 3750